|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.2550 - 0.2774|
|52 Week Range||0.2000 - 0.8000|
|Beta (5Y Monthly)||3.64|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 02, 2021 - Aug 06, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.50|
Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced data from its Phase 4, multi-center, open-label study to assess the efficacy and safety of Acthar® Gel (repository corticotropin injection) in adult patients with treatment-resistant, severe non-infectious keratitis, a disease which involves painful inflammation of the cornea.1 The full results were presented in a poster at The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, and further data will be shared at the upcoming virtual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting. The poster can be accessed here on the company's website.
Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced that data from its Phase 4 observational registry comparing the safety and effectiveness of INOmax® (nitric oxide) gas, for inhalation, in term and near-term (TNT) neonates to that in preterm (PT) neonates with pulmonary hypertension (PH) will be presented in a poster at The Pediatric Academic Societies (PAS) 2021 Virtual Meeting. The poster can be accessed here on the company's website. The safety and efficacy of INOmax in premature neonates has not been evaluated by the U.S. Food and Drug Administration.
Rating Action: Moody's assigns first-time B2 CFR to ANI Pharmaceuticals; outlook stableGlobal Credit Research - 27 Apr 2021New York, April 27, 2021 -- Moody's Investors Service ("Moody's") assigned ratings to ANI Pharmaceuticals, Inc. ("ANI") including a B2 Corporate Family Rating, B2-PD Probability of Default Rating, and a B2 rating to the senior secured credit facilities. Moody's also assigned an SGL-1 Speculative Grade Liquidity Rating.